Rockefeller Capital Management
EGRX

Rockefeller Capital Management’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Rockefeller Capital Management’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-330
Closed -$9K – 4021
2022
Q4 		$9K Buy
330
+285
+633% +$9.06K ﹤0.01% 3149
2022
Q3 		$1K Sell
45
-107
-70% -$3.93K ﹤0.01% 3807
2022
Q2 		$6K Buy
+152
New +$6.98K ﹤0.01% 3401
2021
Q1 		– Sell
-19
Closed – – 3420
2020
Q4 		$0 Buy
+19
New +$889 ﹤0.01% 3038
2020
Q3 		– Sell
-16
Closed -$1K – 2848
2020
Q2 		$1K Buy
+16
New +$798 ﹤0.01% 2530

Other funds holding EGRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Rockefeller Capital Management's EGRX Position: Q1 2023 in Review

Rockefeller Capital Management sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q1 2023, closing a stake of 330 shares — an estimated $9K sold.

Rockefeller Capital Management first reported a position in EGRX in Q2 2020 and held it in 5 quarters. The position peaked at $9K in Q4 2022. 153 funds tracked by Wall St. Rank hold EGRX as of Q1 2023.

  • Rockefeller Capital Management reported no remaining Eagle Pharmaceuticals, Inc. position as of Q1 2023 after selling out during the quarter.
  • Rockefeller Capital Management sold 330 Eagle Pharmaceuticals, Inc. shares in Q1 2023, an estimated $9K.
  • Rockefeller Capital Management first reported a position in Eagle Pharmaceuticals, Inc. in Q2 2020 and held it in 5 quarters.
  • Rockefeller Capital Management's Eagle Pharmaceuticals, Inc. position peaked at $9K in Q4 2022.
  • 153 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q1 2023.

Based on Rockefeller Capital Management's 13F filing for Q1 2023, filed 16 May 2023.